These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 19544287

  • 1. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN.
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR.
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [Abstract] [Full Text] [Related]

  • 10. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T, Lin JH, Baillie TA.
    Toxicol Appl Pharmacol; 2006 Dec 01; 217(2):143-52. PubMed ID: 17055014
    [Abstract] [Full Text] [Related]

  • 11. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA, Obach RS.
    Chem Res Toxicol; 2009 Feb 01; 22(2):267-79. PubMed ID: 19166333
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predicting circulating human metabolites: how good are we?
    Anderson S, Luffer-Atlas D, Knadler MP.
    Chem Res Toxicol; 2009 Feb 01; 22(2):243-56. PubMed ID: 19138063
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ, Mire-Sluis A.
    Nat Biotechnol; 2004 Nov 01; 22(11):1383-91. PubMed ID: 15529163
    [Abstract] [Full Text] [Related]

  • 17. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
    Espina R, Yu L, Wang J, Tong Z, Vashishtha S, Talaat R, Scatina J, Mutlib A.
    Chem Res Toxicol; 2009 Feb 01; 22(2):299-310. PubMed ID: 18980340
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.